Aliskiren hemifumarate

Modify Date: 2024-01-02 19:34:13

Aliskiren hemifumarate structure	Common Name	Aliskiren hemifumarate
	CAS Number	173334-58-2	Molecular Weight	1219.59000
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₆₄H₁₁₀N₆O₁₆	Melting Point	72-75?C
	MSDS	N/A	Flash Point	N/A

Use of Aliskiren hemifumarate

Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.IC50 value: 1.5 nM [1]Target: reninin vitro: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans [2].in vivo: Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets[3].Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension[4].

Name	Aliskiren hemifumarate
Synonym	More Synonyms

Description	Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.IC50 value: 1.5 nM [1]Target: reninin vitro: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans [2].in vivo: Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets[3].Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension[4].
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Metabolic Enzyme/Protease >> Renin Research Areas >> Cardiovascular Disease
References	[1]. Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754–758 [2]. Buczko W, et al. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60(5):623-31. [3]. Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor.Biochem Biophys Res Commun, 2003, 308(4), 698-705. [4]. Gradman AH, et al.Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005, 111(8), 1012-1018.

Description

Related Catalog

Signaling Pathways >> Autophagy >> Autophagy

Signaling Pathways >> Metabolic Enzyme/Protease >> Renin

Research Areas >> Cardiovascular Disease

References

[1]. Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754–758

[2]. Buczko W, et al. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60(5):623-31.

[3]. Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor.Biochem Biophys Res Commun, 2003, 308(4), 698-705.

[4]. Gradman AH, et al.Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005, 111(8), 1012-1018.

Melting Point	72-75?C
Molecular Formula	C₆₄H₁₁₀N₆O₁₆
Molecular Weight	1219.59000
Exact Mass	1218.80000
PSA	366.86000
LogP	9.88180
Vapour Pressure	1.59E-23mmHg at 25°C
Storage condition	Hygroscopic, -20°C Freezer, Under Inert Atmosphere

Hazard Codes	Xi

δN-Benzyloxycar...

CAS#:1236549-06-6

fumaric acid

CAS#:110-17-8

~97%

Aliskiren hemif...

CAS#:173334-58-2

Literature: CHEMO IBERICA, S. A.; CARCONE, Luca; MAGRONE, Domenico; BARRECA, Giuseppe; RASPARINI, Marcello; LI MING, Huan Patent: WO2013/14191 A1, 2013 ; Location in patent: Page/Page column 19; 20 ;

tert-butyl N-[(...

CAS#:173338-07-3

fumaric acid

CAS#:110-17-8

~86%

Aliskiren hemif...

CAS#:173334-58-2

Literature: CHEMO IBERICA, S. A.; CARCONE, Luca; MAGRONE, Domenico; BARRECA, Giuseppe; RASPARINI, Marcello; LI MING, Huan Patent: WO2013/14191 A1, 2013 ; Location in patent: Page/Page column 19 ;

fumaric acid

CAS#:110-17-8

Aliskiren

CAS#:173334-57-1

~81%

Aliskiren hemif...

CAS#:173334-58-2

Literature: JUBILANT LIFE SCIENCES LIMITED; BISWAS, Sujay; SRIMURUGAN, Sankareswaran; KUMAR, Anjul; PANDA, Atulya, Kumar; JAMSHAD, Danish; MASAND, Mukesh; BISWAS, Bidyut; BANSAL, Vikas; GUPTA, Ashish, Kumar; VIR, Dharam Patent: WO2013/61224 A1, 2013 ; Location in patent: Page/Page column 25 ;

Aliskiren Hydro...

CAS#:173399-03-6

fumaric acid

CAS#:110-17-8

Aliskiren hemif...

CAS#:173334-58-2

Literature: WO2003/103653 A1, ; Page 196 ; WO 03/103653 A1

fumaric acid

CAS#:110-17-8

BenzeneoctanaMide

CAS#:324763-47-5

Aliskiren hemif...

CAS#:173334-58-2

Literature: WO2012/52829 A1, ; Page/Page column 16-17 ;

3-Amino-2,2-dim...

CAS#:324763-51-1

Aliskiren hemif...

CAS#:173334-58-2

Literature: WO2011/148392 A1, ;

3-Methylbutanoi...

CAS#:503-74-2

Aliskiren hemif...

CAS#:173334-58-2

Literature: WO2011/148392 A1, ;

3-Amino-2,2-dim...

CAS#:67744-70-1

Aliskiren hemif...

CAS#:173334-58-2

Literature: WO2012/52829 A1, ;

2-cyano-2-methy...

CAS#:7505-93-3

Aliskiren hemif...

CAS#:173334-58-2

Literature: WO2011/148392 A1, ;

Precursor 10
CAS#:1236549-06-6 δN-Benzyloxycar... CAS#:110-17-8 fumaric acid CAS#:173338-07-3 tert-butyl N-[(... CAS#:173334-57-1 Aliskiren
CAS#:173399-03-6 Aliskiren Hydro... CAS#:324763-47-5 BenzeneoctanaMide CAS#:324763-51-1 3-Amino-2,2-dim... CAS#:503-74-2 3-Methylbutanoi...
CAS#:67744-70-1 3-Amino-2,2-dim... CAS#:7505-93-3 2-cyano-2-methy...
DownStream 1
CAS#:173334-57-1 Aliskiren

CGP60536B

Aliskiren fumarate

tekturna

(2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide (2E)-2-butenedioate (2:1)

Aliskiren hemifumarate

(2E)-But-2-endisäure--(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamid(1:2)

Benzeneoctanamide, δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS,γS,δS,ζS)-, (2E)-2-butenedioate (2:1) (salt)

CGP 60536

(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide (2E)-but-2-enedioate (2:1) (salt)

Benzeneoctanamide, δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS,γS,δS,ζS)-, (2E)-2-butenedioate (2:1 ) (salt)

acide (2E)-but-2-ènedioïque - (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-diméthyl-3-oxopropyl)-4-hydroxy-7-[4-méthoxy-3-(3-méthoxypropoxy)benzyl]-8-méthyl-2-(1-méthyléthyl)nonanamide (1:2)

Rasilez

SPP 100

(2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide hemifumarate

benzeneoctanamide, δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS,γS,δS,ζS)-, (2E)-2-butenedioate (2:1

Aliskirenhemifumarate

Aliskiren (hemifumarate)